Log in to save to my catalogue

Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the pha...

Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the pha...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9386661

Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial

About this item

Full title

Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial

Publisher

New York: Nature Publishing Group US

Journal title

Nature medicine, 2022-08, Vol.28 (8), p.1612-1618

Language

English

Formats

Publication information

Publisher

New York: Nature Publishing Group US

More information

Scope and Contents

Contents

Anti-epidermal growth factor receptor (EGFR) monoclonal antibodies are approved for the treatment of
RAS
wild-type (WT) metastatic colorectal cancer (mCRC), but the emergence of resistance mutations restricts their efficacy. We previously showed that
RAS
,
BRAF
and
EGFR
mutant alleles, which appear in circulating tumor DNA (...

Alternative Titles

Full title

Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9386661

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9386661

Other Identifiers

ISSN

1078-8956

E-ISSN

1546-170X

DOI

10.1038/s41591-022-01886-0

How to access this item